Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration
Open Access
- 27 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 23 (1), 1-9
- https://doi.org/10.1186/s13054-019-2568-5
Abstract
Patients with hematologic malignancies who are admitted to hospital are at increased risk of deterioration and death. Rapid response systems (RRSs) respond to hospitalized patients who clinically deteriorate. We sought to describe the characteristics and outcomes of hematologic oncology inpatients requiring rapid response system (RRS) activation, and to determine the prognostic accuracy of the SIRS and qSOFA criteria for in-hospital mortality of hematologic oncology patients with suspected infection. We used registry data from two hospitals within The Ottawa Hospital network, between 2012 and 2016. Consecutive hematologic oncology inpatients who experienced activation of the RRS were included in the study. Data was gathered at the time of RRS activation and assessment. The primary outcome was in-hospital mortality. Logistical regression was used to evaluate for predictors of in-hospital mortality. We included 401 patients during the study period. In-hospital mortality for all included patients was 41.9% (168 patients), and 145 patients (45%) were admitted to ICU following RRS activation. Among patients with suspected infection at the time of RRS activation, Systemic Inflammatory Response Syndrome (SIRS) criteria had a sensitivity of 86.9% (95% CI 80.9–91.6) and a specificity of 38.2% (95% CI 31.9–44.8) for predicting in-hospital mortality, while Quick Sequential Organ Failure Assessment (qSOFA) criteria had a sensitivity of 61.9% (95% CI 54.1–69.3) and a specificity of 91.4% (95% CI 87.1–94.7). Factors associated with increased in-hospital mortality included transfer to ICU after RRS activation (adjusted odds ratio [OR] 3.56, 95% CI 2.12–5.97) and a higher number of RRS activations (OR 2.45, 95% CI 1.63–3.69). Factors associated with improved survival included active malignancy treatment at the time of RRS activation (OR 0.54, 95% CI 0.34–0.86) and longer hospital length of stay (OR 0.78, 95% CI 0.70–0.87). Hematologic oncology inpatients requiring RRS activation have high rates of subsequent ICU admission and mortality. ICU admission and higher number of RRS activations are associated with increased risk of death, while active cancer treatment and longer hospital stay are associated with lower risk of mortality. Clinicians should consider these factors in risk-stratifying these patients during RRS assessment.Keywords
This publication has 54 references indexed in Scilit:
- Rapid-Response TeamsNew England Journal of Medicine, 2011
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Hospital Mortality Rates: How Is Palliative Care Taken into Account?Journal of Pain and Symptom Management, 2010
- Impact of critical care outreach on hematopoietic stem cell transplant recipients: a cohort studyBone Marrow Transplantation, 2010
- Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients: A Reappraisal of Indications for Organ Failure SupportsJournal of Clinical Oncology, 2006
- Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997–2001)Supportive Care in Cancer, 2005
- Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based studyBMJ, 2003
- Surveillance for Nosocomial Infections and Fever of Unknown Origin Among Adult Hematology–Oncology PatientsInfection Control & Hospital Epidemiology, 2002
- Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and ManagementLeukemia & Lymphoma, 2000
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992